Interim Management Statement

RNS Number : 5281I

Victrex PLC

26 July 2012

 



For Stock Exchange release at 7.00 a.m. Thursday 26 July 2012

Victrex plc

Interim Management Statement

This statement comprises Victrex's Interim Management Statement covering the period from 1 April 2012 to date.

Group sales volume has remained strong since the half year end with third quarter volume of 754 tonnes which is marginally ahead of the third quarter of the previous financial year (750 tonnes).

Sales orders for the beginning of the fourth quarter and new business development remain encouraging. However we are mindful of the economic uncertainty, particularly in Europe, and the impact that could have on our customers.

We continue to expect revenue growth year on year from Invibio^®, our biomaterial solutions business, whilst cognisant of the on-going challenges in the US healthcare market.

The Company remains in an excellent financial position with a healthy balance sheet, strong cash generation and no significant changes in its financial position since 31 March 2012.

The Company's annual trading update for the year ending 30 September 2012 will be issued on Thursday 4 October 2012.

Victrex will host a conference call at 9.00am today for analysts. If you would like more details, please contact Rosa Smith at MHPC on 0203 128 8560 / [e-mail].

Enquiries

Victrex plc
Steve Barrow, Finance Director	0203 128 8100 (26 July 2012)
	01253 897 700 (thereafter)
MHP Communications
Nick Denton / Barnaby Fry / Ian Payne	0203 128 8100

Victrex plc is an innovative world leader in high performance materials through the manufacture of VICTREX^® PEEK polymer, a high performance, easy to process thermoplastic.

With over 30 years of experience, Victrex is a global manufacturer of innovative, high performance thermoplastic polymers. We work with customers and end users to deliver technology driven solutions to the challenges and opportunities they face. Our Victrex Polymer Solutions business ('VPS') focuses on our transport, industrial and electronics markets and our Invibio Biomaterial Solutions business ('Invibio') focuses on providing specialist solutions for medical device manufacturers.

 

END

 

 

IMSEAKXSASAAEFF